The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

(2021) Joseph Chao et al.   JAMA Oncology

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

Resistance to Checkpoint Inhibition in Cancer Immunotherapy

(2020) Luisa Barrueto et al.   Translational Oncology

Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).

(2020) Sun Young Rha et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

(2020) Yelena Y Janjigian et al.   LANCET ONCOLOGY

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

(2020) N. Boku et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

(2020) Hyun Cheol Chung et al.   Future Oncology

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion

(2018) Bharat K.R. Chaganty et al.   CANCER LETTERS

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy

(2018) Tiziana Triulzi et al.   OncoImmunology

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit

(2018) Tiziana Triulzi et al.   BRITISH JOURNAL OF CANCER

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Integrated genomic characterization of oesophageal carcinoma

(2017)   NATURE

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

(2017) Yelena Y. Janjigian et al.   Cancer Discovery

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

(2016) V. Varadan et al.   CLINICAL CANCER RESEARCH

Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade

(2015) Philipp Müller et al.   Science Translational Medicine

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

(2014) Eric Van Cutsem et al.   Gastric Cancer

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells

(2013) E. D. Mortenson et al.   CLINICAL CANCER RESEARCH

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER